HomeCompareNVTA vs NOBL

NVTA vs NOBL: Dividend Comparison 2026

NVTA yields 10526.32% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVTA wins by $91421458538285344.00M in total portfolio value
10 years
NVTA
NVTA
● Live price
10526.32%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$91421458538285344.00M
Annual income
$89,744,322,218,307,970,000,000.00
Full NVTA calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — NVTA vs NOBL

📍 NVTA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVTANOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVTA + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NVTA pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVTA
Annual income on $10K today (after 15% tax)
$894,736.84/yr
After 10yr DRIP, annual income (after tax)
$76,282,673,885,561,770,000,000.00/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, NVTA beats the other by $76,282,673,885,561,770,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVTA + NOBL for your $10,000?

NVTA: 50%NOBL: 50%
100% NOBL50/50100% NVTA
Portfolio after 10yr
$45710729269142672.00M
Annual income
$44,872,161,109,153,986,000,000.00/yr
Blended yield
98.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NOBL right now

NVTA
Analyst Ratings
4
Buy
6
Hold
5
Sell
Consensus: Hold
Price Target
$9.75
+51215.8% upside vs current
Range: $2.25 — $17.00
Altman Z
-23.1
Piotroski
4/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVTA buys
0
NOBL buys
0
No recent congressional trades found for NVTA or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVTANOBL
Forward yield10526.32%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$91421458538285344.00M$22.9K
Annual income after 10y$89,744,322,218,307,970,000,000.00$249.78
Total dividends collected$91309952364754128.00M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: NVTA vs NOBL ($10,000, DRIP)

YearNVTA PortfolioNVTA Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$1,063,332$1,052,631.58$10,917$217.08+$1.05MNVTA
2$105,744,905$104,607,140.08$11,903$221.48+$105.73MNVTA
3$9,835,430,757$9,722,283,708.79$12,962$225.68+$9835.42MNVTA
4$855,644,041,989$845,120,131,078.84$14,099$229.68+$855644.03MNVTA
5$69,627,827,846,009$68,712,288,721,080.95$15,319$233.49+$69627827.83MNVTA
6$5,300,152,192,813,391$5,225,650,417,018,161.00$16,628$237.10+$5300152192.80MNVTA
7$377,430,657,448,967,200$371,759,494,602,656,830.00$18,033$240.53+$377430657448.95MNVTA
8$25,145,413,383,015,215,000$24,741,562,579,544,820,000.00$19,539$243.78+$25145413383015.20MNVTA
9$1,567,417,121,474,185,500,000$1,540,511,529,154,359,300,000.00$21,154$246.86+$1567417121474185.50MNVTA
10$91,421,458,538,285,340,000,000$89,744,322,218,307,970,000,000.00$22,884$249.78+$91421458538285344.00MNVTA

NVTA vs NOBL: Complete Analysis 2026

NVTAStock

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Full NVTA Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this NVTA vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVTA vs SCHDNVTA vs JEPINVTA vs ONVTA vs KONVTA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.